Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
142.44
+1.19 (0.84%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Neurocrine Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,374 | 2,861 | 2,355 | 1,887 | 1,489 | 1,134 | |
Revenue Growth | 34.42% | 21.45% | 24.81% | 26.76% | 31.34% | 8.38% |
Cost of Revenue | 1,198 | 1,068 | 765.1 | 604.7 | 487 | 342.4 |
Gross Profit | 2,176 | 1,793 | 1,590 | 1,282 | 1,002 | 791.1 |
Selling, General & Admin | 1,295 | 1,156 | 993.2 | 887.6 | 752.7 | 583.3 |
Operating Expenses | 1,310 | 1,156 | 993.2 | 887.6 | 752.7 | 583.3 |
Operating Income | 866 | 636.5 | 597 | 394.8 | 249 | 207.8 |
Interest Expense | -2.9 | - | - | - | - | -25.8 |
Interest & Investment Income | 88.5 | 90.3 | 91 | 52.8 | 4.1 | 3.8 |
EBT Excluding Unusual Items | 951.6 | 726.8 | 688 | 447.6 | 253.1 | 185.8 |
Gain (Loss) on Sale of Investments | 59.8 | -4 | -37.1 | 28.4 | 30.8 | 20.9 |
Gain (Loss) on Sale of Assets | 28.6 | - | - | - | - | - |
Asset Writedown | - | - | -14 | - | - | - |
Other Unusual Items | - | - | -138.4 | - | -70 | - |
Pretax Income | 940.2 | 705.4 | 486 | 332.1 | 213.9 | 101.4 |
Income Tax Expense | 234.7 | 226.8 | 144.7 | 82.4 | 59.4 | 11.8 |
Net Income | 705.5 | 478.6 | 341.3 | 249.7 | 154.5 | 89.6 |
Net Income to Common | 705.5 | 478.6 | 341.3 | 249.7 | 154.5 | 89.6 |
Net Income Growth | 102.55% | 40.23% | 36.68% | 61.62% | 72.43% | -78.00% |
Shares Outstanding (Basic) | 100 | 100 | 100 | 98 | 96 | 95 |
Shares Outstanding (Diluted) | 104 | 103 | 104 | 101 | 99 | 98 |
Shares Change | 0.78% | -1.16% | 2.67% | 2.12% | 1.02% | 0.10% |
EPS (Basic) | 7.04 | 4.81 | 3.40 | 2.56 | 1.61 | 0.95 |
EPS (Diluted) | 6.82 | 4.67 | 3.29 | 2.47 | 1.56 | 0.92 |
EPS Growth | 101.21% | 41.95% | 33.20% | 58.33% | 69.56% | -77.89% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 870.4 | 748.7 | 557.2 | 361.6 | 322.9 | 233.1 |
Free Cash Flow Per Share | 8.41 | 7.30 | 5.37 | 3.58 | 3.27 | 2.38 |
Gross Margin | 64.48% | 62.67% | 67.52% | 67.96% | 67.29% | 69.79% |
Operating Margin | 25.67% | 22.25% | 25.35% | 20.92% | 16.73% | 18.33% |
Profit Margin | 20.91% | 16.73% | 14.49% | 13.23% | 10.38% | 7.90% |
Free Cash Flow Margin | 25.80% | 26.17% | 23.66% | 19.16% | 21.69% | 20.57% |
EBITDA | 913.3 | 666.6 | 624.1 | 416.1 | 264.6 | 218.7 |
EBITDA Margin | 27.07% | 23.30% | 26.50% | 22.05% | 17.77% | 19.29% |
D&A For EBITDA | 47.3 | 30.1 | 27.1 | 21.3 | 15.6 | 10.9 |
EBIT | 866 | 636.5 | 597 | 394.8 | 249 | 207.8 |
EBIT Margin | 25.67% | 22.25% | 25.35% | 20.92% | 16.73% | 18.33% |
Effective Tax Rate | 24.96% | 32.15% | 29.77% | 24.81% | 27.77% | 11.64% |
Revenue as Reported | 3,374 | 2,861 | 2,355 | 1,887 | 1,489 | 1,134 |
Advertising Expenses | - | 226.8 | 191 | 159.9 | 149.7 | 139.8 |